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Beneficial effects of once-daily liraglutide, a 
human glucagon-like peptide-1 analogue, on 
cardiovascular risk biomarkers in patients 
with Type 2 diabetes
Liraglutide is a once-daily, human glucagon-like peptide-1
(GLP-1) analogue. Clinical studies have demonstrated blood
glucose and weight-reducing effects, improvements in pancreatic
B-cell function and a low risk of hypoglycaemic events with
liraglutide [1,2]. Type 2 diabetes is associated with an increased
risk of cardiovascular events. Recently, studies in patients with
Type 2 diabetes have shown that native GLP-1 may also have
beneficial effects on the myocardium [3] and on endothelial
function [4].
We present here the effect of liraglutide on biomarkers
for cardiovascular risk in patients with Type 2 diabetes, as
an exploratory endpoint from a broader clinical study. The
design and non-cardiovascular biomarker results of this study
have been described previously [1]. The trial was carried out in
accordance with good clinical practice. Briefly, 165 patients
with Type 2 diabetes were randomized to either placebo or
0.65 mg, 1.25 mg or 1.9 mg liraglutide for 14 weeks. Across the
four treatment arms, 17–23% of the subjects were previously
treated with diet and exercise and the remaining subjects with
oral glucose-lowering agents. Subjects had a mean body mass
index (BMI) of 28.9–31.2 kg/m2 and mean glycated haemo-
globin (HbA1c) at randomization of 8.1–8.5%. The study was
powered against the primary endpoint HbA1c, but was not
powered at an 80% level for a difference of 20% for the
cardiovascular biomarkers discussed here. At randomization
and end of study, the following additional parameters were
assessed: adiponectin, leptin, high-sensitivity C-reactive protein
(hs-CRP), interleukin 6 (IL-6), tumour necrosis factor alpha
(TNF-α), plasminogen activator inhibitor 1 (PAI-1) and B-type
natriuretic peptide (BNP).
The data are presented in Table 1. A significant decrease in
PAI-1 and BNP levels were observed following treatment with
liraglutide. There was a non-significant, but dose-dependent,
reduction in hs-CRP levels. There were no treatment effects on
levels of adiponectin, leptin, IL-6 and TNF-α with liraglutide.
This study was part of a larger clinical trial, which showed
significantly improved glycaemic control and a reduction in
body weight in subjects treated with liraglutide [1]. In
addition, systolic blood pressure (reduction of 8 mmHg at
1.90 mg/day vs. placebo) and plasma triglycerides (reduction
of 22% at 1.90 mg/day vs. placebo) were significantly reduced
[1]. PAI-1 and hs-CRP are inflammatory biomarkers that are
associated with an increased risk of cardiovascular disease [5].
Elevated PAI-1 levels may suppress the fibrinolytic process and
thereby be associated with the development of atherosclerosis.
BNP is a marker of left ventricular dysfunction and elevated
levels are risk markers for cardiovascular diseases, in particular
for heart failure [6]. The findings suggest that liraglutide,
when used to regulate blood glucose levels in patients with
Type 2 diabetes, improves certain biomarkers associated with
increased cardiovascular risk. Large prospective trials are
needed to confirm these results and to assess whether these
effects translate into improvements in cardiovascular risk in
patients with Type 2 diabetes.
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Table 1 Baseline levels and change from baseline level of cardiovascular risk markers after 14 weeks of treatment
Cardiovascular biomarker
Baseline level—mean (SD)* 
Liraglutide vs. placebo estimates (95% CI)† 
P-value‡
Placebo 0.65 mg 1.25 mg 1.90 mg
PAI-1 (U/ml) 28.2 ± 20.0 27.8 ± 32.4 22.0 ± 13.0 31.4 ± 28.4
−14% (−35%; 14%) −29% (−47%; −6%) −25% (−43%; −1%)
0.29 0.018§ 0.045§
BNP (ng/l) 42.8 ± 42.7 35.1 ± 22.9 45.0 ± 38.4 40.6 ± 38.6
−26% (−48%; 6%) −30% (−52%; −0%) −38% (−57%; −12%)
0.099 0.048§ 0.0085§
Adiponectin (ng/ml) 4964 ± (3877) 4895 ± 2504 5713 ± 3415 3872 ± 2210
6% (−7%; 20%) 6% (−7%; 20%) 3% (−10%; 17%)
0.37 0.39 0.67
Leptin (pg/ml) 16 242 ± (12 717) 11 815 ± 11 991 13 724 ± 9105.8 10 812 ± 9249.7
14% (−2%; 32%) 26% (9%; 46%) 9% (−6%; 26%)
0.085 0.0017§ 0.27
hs-CRP (mg/l) 4.3 ± (4.0) 3.1 ± 2.1 3.9 ± 3.3 4.2 ± 4.2
−3% (−32%; 38%) −12% (−38%; 25%) −20% (−44%; 14%)
0.85 0.46 0.22
IL-6 (pg/ml) 3.6 ± (3.9) 2.5 ± 1.7 10.6 ± 52.4 2.8 ± 1.7
−3% (−25%; 26%) 4% (−20%; 34%) −2% (−25%; 27%)
0.83 0.79 0.87
TNF-α (pg/ml) 2.3 ± (1.5) 2.4 ± 1.5 2.0 ± 0.9 2.4 ± 2.3
−6% (−19%; 8%) 1% (−12%; 16%) −4% (−17%; 11%)
0.37 0.90 0.58
*Mean ± SD of baseline values.
†Difference from placebo in change from baseline level in per cent, with 95% confidence interval.
‡P-value for change.
The cardiovascular risk biomarker parameters have been log transformed before applying the statistical model. Estimates are presented as per 
cent change. The estimates are obtained from an ANOVA with treatment and previous treatment as fixed effect and baseline value as covariate. 
§Statistical significance at the 5% significance level.
BNP, B-type natriuretic peptide; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; PAI-1, plasminogen 
activator inhibitor 1; SD, standard deviation; TNF-α, tumour necrosis factor alpha. 
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Gelling of insulin within an insulin pump 
reservoir
Herein I report a unique case of gelled solidification of insulin
within an insulin reservoir and tubing in a patient with Type 1
diabetes treated with continuous subcutaneous insulin
infusion (CSII) therapy.
A 29-year-old pregnant woman with a 21 year history of
Type 1 diabetes, maintaining excellent blood glucose [blood
glucose levels 4.0–7.5 mmol/l; glycated haemoglobin (HbA1c)
6.0%] with CSII therapy using insulin lispro administered by
a Medtronic Paradigm 712 pump (using a Quick-Set infusion
set Medtronic Diabetes, Northridge, CA, USA), experienced
sudden deterioration in blood glucose control with readings
climbing to the high teens over a few hours. Corrective
boluses of insulin were administered without improvement,
at which point the patient inspected her insulin reservoir and
observed the insulin to have gelled (Fig. 1). She reverted to
conventional insulin injection and euglycaemia was restored
quickly. Inspection of the vial itself revealed that it, unlike the
reservoir, was free of solidification.
The patient subsequently obtained a new lot of insulin and,
after several weeks of uneventful use, experienced the same
phenomenon. She then switched to yet another insulin lot and
no further problems were encountered.
Although crystallization of insulin administered by CSII has
been identified previously [1,2], gelling of insulin within an
insulin pump reservoir has not, as far as I am aware, been
previously reported. Eli Lilly (pers. comm.), the manufacturer
of the insulin in question, has advised me that insulin lispro can
gel within a vial if the insulin is exposed to excess heat, overly
vigorous shaking or if syringes and needles to withdraw the
insulin are reused. The patient described herein had not exposed
her insulin vial (or reservoir or pump) to excess heat, cold or
humidity, had not subjected it to shaking, had not reused her
syringes or needles and had not reused her insulin reservoir.
Analysis of the insulin vial by Eli Lilly revealed the presence
of silicon (pers. comm.) thought to be related to piercing of the
rubber stopper by the needle when drawing up insulin. Analysis
of the contents of the gelled substance was requested, but not
performed.
The aetiology of the gelling of the insulin is not known.
However, as this hitherto unreported gelling of insulin within
an insulin pump reservoir occurred twice in the same patient
and with two different insulin lots, some patient-specific factor
cannot be excluded. Regardless, individuals using CSII therapy
and those assisting with their healthcare management will
need to consider insulin gelling when determining the cause of
sudden deterioration in blood glucose control.
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FIGURE 1 Gelled insulin within the insulin reservoir.
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